+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative studies on hem agglutinating activity and immunogenicity of bovine parainfluenza virus type 3 strains



Comparative studies on hem agglutinating activity and immunogenicity of bovine parainfluenza virus type 3 strains



Acta Veterinaria Academiae Scientiarum Hungaricae 30(1-3): 45-50



Studies on parainfluenza virus type 3 (PI-3) strains isolated from 6-8 wk old and 5-12 mo. old calves affected by different respiratory diseases revealed that isolates of identical infective titers markedly differed in their hemagglutinating (HA) activity, and that virus strains maintained this property through several passages. PI-3 virus strains of high HA activity were exposed to physical or chemical treatments. Heat treatment at 50.degree. C for 120 min or treatment with 0.5% trypsin for 30 min destroyed both the infectivity and the HA activity of the virus. Heat treatment at 50.degree. C for 80 min or treatment with 0.25% trypsin for 30 min, destroyed the HA activity of the virus but did not affect its infectivity. Formaldehyde and .beta.-propiolactone treatment destroyed the infectivity of the virus and damaged its hemagglutinins to different extents. Ethylenimine (EI) was found to inactivate the infectivity of PI-3 virus but failed to affect its HA activity. The immunogenicity of virus strains or originally high and originally low HA activity and damaged in different ways showed a positive correlation with the HA activity of the strains. Rabbits inoculated twice with an EI-inactivated PI-3 virus developed hemagglutination-inhibiting (HI) antibodies after the 1st vaccination. Marked elevation of virus-neutralizing (VN) antibody titers needed a 2nd vaccination.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 004999092

Download citation: RISBibTeXText


Related references

Immunogenicity of a modified-live virus vaccine against bovine viral diarrhea virus types 1 and 2, infectious bovine rhinotracheitis virus, bovine parainfluenza-3 virus, and bovine respiratory syncytial virus when administered intranasally in young calves. Vaccine 28(22): 3784-3792, 2010

Recombinant type 5 adenoviruses expressing bovine parainfluenza virus type 3 glycoproteins protect Sigmodon hispidus cotton rats from bovine parainfluenza virus type 3 infection. Journal of Virology 69(7): 4308-4315, 1995

Evaluation of the safety, immunogenicity and virus shedding of an intranasal live attenuated Bovine parainfluenza virus type 3 vaccine in infants. Pediatric Research 45(4 Part 2): 161A, 1999

Bovine parainfluenza type 3 virus vaccine safety and immunogenicity in infants and young children. Pediatric Research 31(4 Part 2): 166A, 1992

Serological studies of parainfluenza type 3 virus, bovine adenovirus type 3 and bovine respiratory syncytial virus infection in beef calves. Veterinary Microbiology 9(6): 587-592, 1984

Immunogenicity of bovine parainfluenza type 3 virus proteins encapsulated in nanoparticle vaccines, following intranasal administration to mice. Research in Veterinary Science 74(2): 187-190, 2003

Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys. Journal of General Virology 84(Pt 12): 3253-3261, 2003

Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. Journal of Virology 77(20): 10819-10828, 2003

Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. Journal of Virology 74(24): 11626-11635, 2000

Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection. Journal of Virology 88(8): 4237-4250, 2014

Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. Journal of Virology 76(3): 1089-1099, 2002

Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge. Journal of Infectious Diseases 157(4): 655-662, 1988

Comparative analysis of the immunostimulatory properties of different adjuvants on the immunogenicity of a prototype parainfluenza virus type 3 subunit vaccine. Vaccine 10(6): 412-420, 1992

Antigenic variation of human and bovine parainfluenza virus type 3 strains. Journal of General Virology 71: 1577-1580, 1990

Comparative study of the hem agglutinating activity of different rubella virus strains. Voprosy Virusologii (4): 459-463, 1974